Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 750 shares at $16.50 ($12K) on 2023-06-26, disclosed to the SEC on 2023-06-27.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |